OpenAI and FDA Discuss AI for Drug Evaluation

OpenAI has been in discussions with the FDA about using artificial intelligence to accelerate drug evaluations. These talks have centered around a project known as cderGPT, which aims to assist the Center for Drug Evaluation in regulating over-the-counter and prescription drugs in the U.S., as reported by Wired.

The meetings, which have included associates from Elon Musk's Department of Government Efficiency, are part of a broader FDA initiative to modernize the drug approval process with AI technology. The FDA's AI officer, Jeremy Walsh, has been leading these discussions, although no formal agreements have been made yet.

The FDA has been exploring AI's potential to streamline the drug review process, which traditionally takes about a year. While AI could help shorten this timeline, questions remain about the reliability of AI models in such critical applications. The FDA has existing mechanisms to expedite drug evaluations, such as fast track and breakthrough therapy designations, but integrating AI could further enhance these processes.